OxTalks is Changing
Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
Inhaled corticosteroids treatment for CoVID-19: The Stoic Study
At the time of writing over five million people have been infected by the SARS-CoV-2 coronavirus around the world.
The severe clinical condition that leads to deaths is now called CoVID-19. Currently, there are no effective treatments for the early or late stages of this illness. Governments worldwide have undertaken dramatic interventions to try and reduce the rate of spread of this deadly coronavirus.
Early data from multiple studies in China, where the virus originated, show that severe cases of CoVID-19 are not as prevalent in patients with chronic lung diseases as expected. This is similar to findings from Italy and the US. We think that the widespread use of inhaled corticosteroids may be reducing the risk of severe CoVID-19 infection in patients with chronic lung disease. Early experimental data also shows that inhaled corticosteroids are effective at slowing down the rate of coronavirus replication on lung cells.
Inhaled corticosteroids are widely used to manage common lung conditions, such as asthma and chronic obstructive lung disease. This type of medicine is among the top 3 most common medication prescribed around the world. These medicines are safe, the way inhaled steroids work is well understood, and the potential side effects are mild and reversible.
We propose to test the idea that, in participants early in the course of CoVID-19 illness, daily inhaled corticosteroids for a maximum of 28 days, will reduce the chances of severe respiratory illness needing hospitalisation. We will also study the effect of this inhaled therapy on physiology, symptoms and the amount of virus that is shed.
Date:
31 March 2021, 12:30
Venue:
This seminar will be held as a webinar. Please email samantha.thulborn@ndm.ox.ac.uk for the link to the event.
Speaker:
Professor Mona Bafadhel (University of Oxford)
Organising department:
NDM Experimental Medicine
Organiser:
Professor Ian Pavord (University of Oxford)
Organiser contact email address:
samantha.thulborn@ndm.ox.ac.uk
Part of:
Respiratory Medicine BRC themed seminar series
Booking required?:
Not required
Audience:
Members of the University only
Editor:
Samantha Thulborn
